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Re: Depression as a Risk Factor
for Cancer: Renewing a Debate
on the Psychobiology of Disease
Croyle (1), in his excellent editorial
regarding the very fine study by Penninx
et al. (2), suggested that three areas of
follow-up research would be indicated
to further delineate the association be-
tween depression and cancer. One of
those recommendations was to extend
the study of a younger population, be-
cause it may be that the mechanisms re-
sponsible for the relationship between
depression and cancer are related to the
aging process.
I don’t anticipate that a negative
study in younger patients would justify
the conclusion that aging is the cause of
the association between depression and
cancer death that was found in the study
by Penninx et al. (2). Cancers in general
have a long latency. As pointed out by
Croyle, stress and depression have been
associated with the causation and accel-
eration of cardiovascular disease. Car-
diovascular disease tends to cause death
at a younger age than does cancer.
Therefore, one would have a common
risk factor (for cardiovascular disease
and cancer) and a competing cause of
death (from cardiovascular disease and
cancer), which would confound any epi-
demiologic study where death from can-
cer is in part or in whole an end point.
I think the main value of studies in
younger patients would be to determine
whether stress and depression can have
an effect on the recurrence or progres-
sion of cancer. The fact that such an as-
sociation is being found more frequently
(3) would lend further credence to the
study by Penninx et al.
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RESPONSE
A replication of our findings—that
chronically depressed mood increases
risk of cancer—in younger populations
will give further credence to this link.
However, if we are unable to find an
association between chronically de-
pressed mood and cancer in younger
populations, this could indicate that age
is indeed a modifier of the association
between chronically depressed mood
and cancer. The effect of many risk fac-
tors is attenuated with increasing age.
Therefore, finding that the association
between chronic depression and cancer
is stronger at older age would provide
provocative evidence that a synergistic
effect exists between chronic depression
and changes in aging that are known to
increase vulnerability to cancer.
In our study, we did not have data
available about the stage of cancer when
diagnosed and the progression speed of
the cancer. Consequently, other studies
in both young and old populations
should provide further information
about the association between chronic
depression and recurrence or progres-
sion of cancer. If these studies are posi-
tive, they would add further support to
our findings, but studies of stage and
progression of cancer may not neccesar-
ily reflect the same risk factors as those
for incidence. All of these studies are
needed to learn about possible pathways
in the link between chronic depression
and cancer. We would like to emphasize
that further studies should focus on
people with chronic depression because
the most important implication of our
study is that long-term depression in-
creases risk for cancer.
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titumor effects of Linomide. In an edi-
torial accompanying the article by Jo-
seph and Isaacs, Wahl and Kleinman (2)
suggested, on the other hand, that tumor
therapy protocols that combine Lino-
mide with the antiangiogenic cytokine
interleukin 12 (IL-12)—which induces
interferon-gamma release and activates
rather than inhibits TAMs—would be
worth pursuing.
The results of our present studies
demonstrate the pertinence of this sug-
gestion. In a murine melanoma model,
in which the antitumor activity of Lino-
mide has already been demonstrated (3),
we show that administration of IL-12 in
combination with Linomide results in
potentiated antitumor effects over
single-agent therapy (two-sided P<.05;
Mann–Whitney U test) (Fig. 1).
To confirm that IL-12 and Linomide,
used alone or in combination, exert the
antiangiogenic effects that were ex-
pected on the basis of previous reports,
we used a tumor-induced angiogenesis
model. This model was proven effective
in a previous study of IL-12 and tumor
necrosis factor (5). Short-term (3 con-
secutive days) intraperitoneal adminis-
tration of either 0.1 mg IL-12 or 400 mg
Linomide resulted in significant inhibi-
tion of blood vessel formation at the site
of B16F10 murine melanoma cell injec-
tion (16.4 blood vessels per microscope
field [95% confidence interval {CI} 4
14.7–18.1 vessels] and 16.0 blood ves-
sels per field [95% CI 4 15.2–16.8 ves-
sels] in IL-12 and Linomide-treated
mice, respectively) as compared with
diluent-injected controls (18.7 vessels
per field [95% CI 4 17.8–19.5 blood
vessels]; two-sided P 4 .007 for IL-12
versus control group; two-sided P 4
.0003 for Linomide versus control
group; Mann–Whitney U test). Com-
bined treatment with IL-12 and Lino-
mide was statistically significantly more
effective in inhibiting the formation of
new blood vessels than was the treat-
ment with either agent alone (13.7 blood
vessels per field [95% CI 4 12.3–15.1
vessels]; two-sided P 4 .012 for IL-12
versus combined treatment group; two-
sided P 4 .0028 for Linomide versus
combined treatment group).
Our results demonstrate potentiation
of antitumor and antiangiogenic effects
for combination therapy with IL-12
and Linomide in a murine melanoma
model. These observations would ap-
pear to be clinically interesting because
antitumor efficacy of both these agents
is currently being evaluated in clinical
trials (6,7).
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Fig. 1. Effects of treatment
with interleukin 12 (IL-12)
and/or Linomide® on
B16F10 melanoma growth
(IL-12 was a gift from the
Genetics Institute Inc., Bos-
ton, MA, and Linomide was
a gift from Pharmacia and
Upjohn, Lund, Sweden).
B6D2F1 mice were inocu-
lated with 1 × 106 mela-
noma cells in the footpad of
the right hind limb and
treated intratumorally with
0.1 mg IL-12 for 7 consecu-
tive days and/or intraperito-
neally with 400 mg/kg of
Linomide for 21 days start-
ing on day 7 after inocula-
tion of tumor cells. As a
control, the following diluents were used: 0.1% bovine serum albumin–phosphate-buffered saline (PBS)
administered intratumorally for 7 consecutive days and 0.01% Tween in PBS administered intraperito-
neally for 21 consecutive days. Groups consisted of seven to eight mice. Doses of IL-12 and Linomide
were established in previous experiments (data not shown). Tumor growth was monitored as described
previously (4). Tumor volumes are expressed as means with 95% confidence intervals. * = two-sided P
<.05 as compared with all other groups (Mann–Whitney U test). l 4 control; d 4 IL-12; h 4
Linomide; and , 4 IL-12 + Linomide.
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